Contineum Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$60MTTM through 30 Jun 2026
Free Cash Flow -$53.5MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-23.4%ROE
-22.4%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio37.99x
Net Debt-$246.3Mnet cash position
Cash & Equivalents$14.7M
Quality Metrics
Altman Z-Score27.33
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2024: $0
Diluted EPS-$1.72TTMFY2025: $-2.17
Dividend
No dividend
Capital Allocation
R&D Spend$48.1M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| PIPE-791 | $0 | View detailsTopline data from the exploratory Phase 1b trial in chronic pain is expected in the second quarter of 2026. | |
| PIPE-307 | $0 | View detailsJ&J is currently conducting a Phase 2 Moonlight-1 trial in major depressive disorder. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.